Case 1:20-cv-01644-RGA Document 1-27 Filed 12/03/20 Page 1 of 3 PageID #: 933
`Case 1:20-cv-01644-RGA Document 1-27 Filed 12/03/20 Page 1 of 3 PageID #: 933
`
`
`
`
`
`EXHIBIT 27
`
`
`
`
`
`EXHIBIT 27
`
`
`
`
`
`
`

`

`10/28/2020
`
`Leading non-invasive prenatal test now available through Viapath | Viapath
`Case 1:20-cv-01644-RGA Document 1-27 Filed 12/03/20 Page 2 of 3 PageID #: 934
`
`Menu
`
`Leading non-invasive prenatal test now available through Viapath
`
`Wednesday, 16 July, 2014
`
`Viapath is proud to be the sole provider of the verifi® non-invasive prenatal test in the South East of England.
`
`1.
`2.
`3.
`4.
`5.
`
`Peace of mind for pregnant women
`Very low test failure rates (<0.1%)
`Unrivalled turnaround time (circa six days from sample taken to Viapath report)
`Peer reviewed, published clinical data available
`Single blood sample required
`
`Non-invasive prenatal testing is a new and exciting procedure for screening pregnancies for common chromosome abnormalities.
`Fetal genetic material is present in the circulation of pregnant women and analysis of 7-10ml of maternal blood can identify
`pregnancies at very high risk of having conditions such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau
`syndrome (trisomy 13).
`
`“verifi® is a non-invasive prenatal test with the lowest test failure rate of any other test in its class” states Professor Caroline
`Ogilvie, Professor of Cytogenetics and Consultant Scientist at our Genetics Department at Guy's Hospital, London.
`
`“This test is available to pregnant women from 10 weeks gestation, and verifi®’s turn around times are impressive”, says Dr Kathy
`Mann, Principal Clinical Scientist at our Cytogenetics Laboratory also at Guy’s Hospital.
`
`The verifi® test is performed by Illumina, based in the U.S.; samples are collected by Viapath Genetics Laboratory located in Guy’s
`Hospital and sent to the U.S. for testing. Clinical interpretation and support is provided by the Viapath Genetics Laboratory.
`
`Although this test is available to all women, those who are older or who have a raised risk following standard Down syndrome
`screening, are most likely to benefit. For women with pregnancies that show ultrasound anomalies, chorionic villus or amniocentesis
`testing are more appropriate, as other chromosome abnormalities may be present that are not detected by non-invasive prenatal
`testing.
`
`Information forms are available for clinics who wish to access this test for their patients. Streck tubes for collecting maternal blood
`will be provided by Viapath.
`
`Click here for more information on our new non-invasive prenatal test at Guy's Hospital, including our full test
`repertoire and recent publications.
`
`www.viapath.co.uk/news-and-press/leading-non-invasive-prenatal-test-now-available-through-viapath
`
`1/2
`
`

`

`10/28/2020
`
`Leading non-invasive prenatal test now available through Viapath | Viapath
`Case 1:20-cv-01644-RGA Document 1-27 Filed 12/03/20 Page 3 of 3 PageID #: 935
`
`eMail alerts and news
`
`Follow us
`
`Menu
`
`Sign up with Viapath to receive our newsletter and hear
`about our scientific events.
`
`e-mail address
`
`SUBMIT
`
`Privacy policy
`
`Site details
`
`Privacy, data and cookie policy
`
`Terms of use
`
`Accessibility
`
`Sitemap
`
`Feedback
`
` 
`
`Working with our NHS service partners to set the standard for the future of pathology
`
`
`
`Viapath is a founding member of The Association of Independent Pathology Providers (AIPP), which is a trade association representing innovative research-based diagnostic testing
`
`companies. www.pathologyassociation.com
`
`Copyright 2014 Viapath Group LLP. Viapath, the Viapath logo and Nutris are registered trademarks of Viapath Group LLP.
`
`www.viapath.co.uk/news-and-press/leading-non-invasive-prenatal-test-now-available-through-viapath
`
`2/2
`
`